XNCR

PASADENA, Calif. (AP) — PASADENA, Calif. (AP) — Xencor Inc. (XNCR) on Wednesday reported a loss of $128.9 million in its first quarter. On a per-share basis, the Pasadena, California-based company said it had a loss of $1.71. The results did not meet Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for a loss of 65 cents per share. The biotech developing antibodies for severe autoimmune/allergic diseases and cancer posted revenue of $4.5 million in the period, also falling short of Street forecasts. Six analysts surveyed by Zacks expected $18.3 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on XNCR at https://www.zacks.com/ap/XNCR

-- XmAb819 clear cell renal cell carcinoma (ccRCC) expansion cohort results to be presented at a medical conference in 2H26 -- -- XmAb412 (TL1A x IL23p19) first-in-human healthy participant study on-track for 3Q26 start -- -- Plamotamab and XmAb657 autoimmune studies on-track for 2H26 progress update -- PASADENA, Calif., May 06, 2026--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2026. "Xencor continues to execute across our wholly owned clinical pipeline, with significant progress in both oncology and autoimmune disease. We look forward to presenting expansion cohort data from our Phase 1 study of XmAb819 for the treatment of advanced clear cell renal cell carcinoma at a medical meeting in the second half of 2026, which will help support the initiation of our first pivotal study planned for 2027," said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor. "Our TL1A pipeline continues to advance with strong enrollment in the global Phase 2b XENITH-UC Study of XmAb942 in ulcerative colitis supported by investigator enthusiasm for its potential best-in-class profile in moderately to severely active ulcerative colitis. We expect to complete a blinded interim analysis around year-end 2026 and complete the primary endpoint analysis for the study’s 12-week induction period during the second half of 2027. We also look forward to initiating the first-in-human study of XmAb412, our novel TL1A x IL23p19 bispecific antibody, in the third quarter of 2026. XmAb412 utilizes our novel XenLock™ Fab domain platform, which enables multi-specific biologics designed to address the very stringent requirements for high potency, long half-life and low immunogenicity in the treatment of autoimmune and inflammatory disease." Wholly Owned Pipeline Overview XmAb819 (ENPP3 x CD3), a first-in-class, tumor-targeted T-cell engaging XmAb® 2+1 bispecific antibody in development for patients with advanced clear cell renal cell carcinoma (ccRCC). Xencor plans to present expansion cohort data from the ongoing Phase 1 study to define a recommended Phase 3 target dose at a medical conference in 2H26 and support initiation of a pivotal study of XmAb819 in ccRCC planned for 2027. Tumo...

PASADENA, Calif. (AP) — PASADENA, Calif. (AP) — Xencor Inc. (XNCR) on Wednesday reported a loss of $6.7 million in its fourth quarter. The Pasadena, California-based company said it had a loss of 9 cents per share. The results beat Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of 64 cents per share. The biotech developing antibodies for severe autoimmune/allergic diseases and cancer posted revenue of $28.2 million in the period, also exceeding Street forecasts. Six analysts surveyed by Zacks expected $21.6 million. For the year, the company reported a loss of $91.9 million, or $1.24 per share. Revenue was reported as $125.6 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on XNCR at https://www.zacks.com/ap/XNCR

-- XmAb819, novel first-in-class ENPP3 x CD3 T-cell engaging bispecific antibody, Phase 1 dose expansion in CRC, NSCLC and pRCC open to enrollment; on track to present clinical data to support a recommended Phase 3 dose in ccRCC in 2H26 -- -- Final results from healthy-volunteer study of Xmb942, Xtend™ TL1A antibody, and preclinical characterization of XmAb412, TL1A x IL23p19 XmAb® bispecific antibody, to be presented at DDW 2026 -- PASADENA, Calif., February 25, 2026--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025. "Xencor’s lead oncology drug candidate is XmAb819, a novel first-in-class T-cell engager that could offer a much-needed new therapeutic modality for patients with advanced clear cell renal cell carcinoma (ccRCC). Excitement from the clinical community on our initial data from the dose-escalation study presented during ENA 2025 supports achieving our goal of presenting dose-expansion data during a medical meeting in the second half of 2026 and our plans to initiate a pivotal study during 2027," said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor. "Building on the early success in ccRCC, we recently opened additional dose expansion cohorts in other tumor types that have high ENPP3 expression: colorectal cancer, non-small cell lung cancer and papillary renal cell carcinoma." "In 2026, we plan to present additional key clinical data and progress updates as we also advance XmAb541 and our ongoing B-cell depleting autoimmune programs, respectively. Our TL1A pipeline in inflammatory bowel disease continues to advance, as well. We are making great progress with enrollment in our Phase 2b XENITH-UC study of XmAb942 and are excited to begin the first-in-human study of XmAb412, our novel TL1A x IL23p19 bispecific antibody in the second half of 2026. We are proud of our execution across an evolved clinical pipeline and of the Xencor team’s focus on designing proteins to deliver novel medicines for patients." Wholly Owned Pipeline Overview XmAb819 (ENPP3 x CD3), a first-in-class, tumor-targeted T-cell engaging XmAb® 2+1 bispecific antibody in development for patients with advanced clear cell renal cell carcinoma (ccRCC...

Xencor (XNCR) just shared its third quarter earnings, revealing a sharp reduction in net loss compared to a year ago. Investors are paying close attention as the company’s financial turnaround continues to take shape. See our latest analysis for Xencor. Xencor’s dramatic improvement in net losses seems to have caught the market’s eye. Its share price has climbed 82% over the past 90 days. That momentum follows a tough year, as the 12-month total shareholder return remains deeply negative, but recent earnings events may be shifting sentiment and fueling hopes for a turnaround. If you’re tracking Xencor’s rebound and want to spot other healthcare innovators on the move, you can explore the sector further with our hand-picked See the full list for free.. Given Xencor’s recent surge, is the market still underestimating its turnaround story? Or has the swift rally already priced in all the company’s future growth, leaving little room for new upside? Xencor’s most widely followed narrative sees the stock trading well below what the consensus considers fair value, given its current price of $13.99. The narrative’s fair value estimate lands at $27.64, suggesting a notable gap between market sentiment and analysts’ long-term earnings outlook. Read the complete narrative. What is the real engine behind this optimistic valuation? Explore a forecast built on ambitious future margins and a potential profit leap that could spark a total re-rating. This narrative contains some eye-opening expectations. Are you ready to uncover the fulcrums driving Xencor’s price target? Result: Fair Value of $27.64 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, doubts remain because key clinical trials still need to deliver robust results, and delays or a lack of conclusive data could dampen future optimism. Find out about the key risks to this Xencor narrative. If you have a different perspective or want to dive deeper into the numbers, you can easily craft your personal Xencor story in just minutes: Do it your way. A great starting point for your Xencor research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision. Why stop with Xencor when there are so many promising opportunities across the market? See what you could be missing out on and give your portfolio an extra e...

PASADENA, Calif., November 05, 2025--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the third quarter ended September 30, 2025 and provided recent business and clinical program updates. "Xencor’s two novel, first-in-class, CD3 T-cell engaging bispecific antibodies, XmAb819 and XmAb541, have demonstrated compelling clinical data in advanced clear cell renal cell carcinoma and advanced gynecologic and germ cell tumors, respectively. As we continue to advance through dose escalation and cohort expansions in Phase 1 studies evaluating these programs, we expect to identify recommended Phase 3 doses during 2026 to support initiation of pivotal studies during 2027," said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor. "The accelerating tempo of clinical development extends to our autoimmune portfolio. In the third quarter we dosed the first patient in our Phase 2b XENITH-UC study of XmAb942, our potential best-in-class antibody targeting TL1A for inflammatory bowel disease, to rapidly identify a pivotal dose regimen for those with moderately to severely active ulcerative colitis, and we dosed the first patient in our Phase 1b study of plamotamab in rheumatoid arthritis. We remain on-track to start clinical studies of XmAb657, our B-cell depleting TCE for the treatment of patients with autoimmune disease by year end 2025, and our lead TL1A x IL23p19 bispecific antibody, now designated XmAb412, in 2026." Clinical Program Updates Oncology XmAb819 (ENPP3 x CD3), a novel, first-in-class, tumor-targeted T-cell engaging XmAb® 2+1 bispecific antibody in development for patients with advanced clear cell renal cell carcinoma (ccRCC). The first dose-expansion cohort in the ongoing Phase 1 study is enrolling patients as dose-escalation continues. Xencor plans to select a recommended Phase 3 dose during 2026 to support initiation of a pivotal study in advanced ccRCC during 2027. At the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics in October 2025, Xencor presented initial results from the ongoing Phase 1 dose-escalation study of XmAb819. As of the data cut-off, 69 patients had received XmAb819 across 15 dose cohorts; patients were heavily pre-treated, having received a...

PASADENA, Calif. (AP) — PASADENA, Calif. (AP) — Xencor Inc. (XNCR) on Wednesday reported a loss of $6 million in its third quarter. The Pasadena, California-based company said it had a loss of 8 cents per share. The results topped Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 72 cents per share. The biotech developing antibodies for severe autoimmune/allergic diseases and cancer posted revenue of $21 million in the period, missing Street forecasts. Six analysts surveyed by Zacks expected $25.7 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on XNCR at https://www.zacks.com/ap/XNCR

Xencor (XNCR) recently shared initial results from its ongoing Phase 1 trial of XmAb819, a new bispecific antibody, in advanced renal cell carcinoma. The announcement at a major oncology conference has prompted investors to take notice. See our latest analysis for Xencor. Xencor’s announcement of early data on XmAb819 appears to have reignited some optimism after a tough stretch, with the shares up 23% over the past month and surging more than 63% in the last 90 days, even as the year-to-date share price return is still well in the red. Long-term holders are still facing a negative 33.9% total shareholder return over the past year, and the five-year picture remains deeply underwater, but recent momentum suggests the market is re-evaluating Xencor’s prospects as the pipeline matures. If breakthrough biotech updates spark your interest, consider exploring more companies in the sector using our healthcare stock discovery tool: See the full list for free. With shares rebounding sharply following early clinical data, the question now is whether Xencor remains undervalued compared to analyst targets or if the recent run-up means future growth is already accounted for. Compared to Xencor’s latest closing price of $14.25, the narrative’s fair value sits substantially higher. This prompts attention from those watching for a turnaround and sets the stage for a closer look at what could be driving such a valuation gap. Read the complete narrative. Want to unlock the bold math behind this valuation? The price target is powered by ambitious margin moves and an aggressive profit future you might not expect from a biotech turnaround. Intrigued by what assumptions drive such dramatic upside? Discover the key drivers fueling this optimistic view. Result: Fair Value of $25.73 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, significant delays in late-stage trials or failure to demonstrate clear product differentiation could quickly undermine the current optimism surrounding Xencor’s outlook. Find out about the key risks to this Xencor narrative. If you have a different take or want to shape your own perspective, it only takes a few minutes to explore the underlying data and build a fresh view. Do it your way. A great starting point for your Xencor research is our analysis highlighting 1 key reward and 2 important warning...

PASADENA, Calif., October 21, 2025--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will host a conference call and webcast on Friday, October 24 at 1:30 p.m. ET (10:30 a.m. PT) to discuss initial results from the ongoing Phase 1 dose-escalation study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in development for patients with advanced clear cell renal cell carcinoma. The live webcast of the conference call may be accessed through this link and through "Events & Presentations" in the Investors section of the Company’s website, located at investors.xencor.com. A recording will be available for at least 30 days. The results will be presented at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts, during Poster Session B on Friday, October 24 from 12:30 to 4:00 p.m. ET in a poster titled "Preliminary Phase 1 safety and antitumor activity of XmAb819, a first-in-class ENPP3 x CD3 bispecific antibody, in patients with advanced clear cell renal cell carcinoma (ccRCC)." About XmAb819 XmAb819 is a first-in-class, tumor-targeted, T-cell engaging XmAb 2+1 bispecific antibody in development for patients with clear cell renal cell carcinoma (ccRCC). XmAb819 engages the immune system and activates T cells for highly potent and targeted lysis of tumor cells expressing ENPP3, an antigen highly expressed on kidney cancers. ENPP3 is a differentially expressed target, with high level expression in renal cell carcinoma (RCC) and low-level expression on normal tissues. With two tumor-antigen binding domains and one T-cell binding domain, Xencor’s XmAb® 2+1 format enables antibodies to bind more avidly and selectively kill tumor cells with higher antigen density, potentially sparing normal cells. Xencor is conducting a Phase 1 study to evaluate XmAb819 in patients with advanced ccRCC. About Xencor Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and multiple XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein’s structure that result i...

-- Management to host webcast and conference call on Friday, October 24, 2025 -- PASADENA, Calif., October 14, 2025--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the upcoming presentation of initial results from the ongoing Phase 1 dose-escalation study of XmAb819, a bispecific ENPP3 x CD3 T-cell engaging bispecific antibody, in patients with clear cell renal cell carcinoma (ccRCC) in a poster at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics, being held October 22-26, 2025 in Boston, Massachusetts. Today, Xencor management also became aware that an investment bank published takeaways from the abstract accepted for presentation at the conference, which is not publicly available via the conference website or app. Full abstracts are scheduled to be released by the conference next Wednesday, October 22 at 12 p.m. ET. Xencor submitted a placeholder abstract with limited detail based on a previous data-cut from the ongoing dose-escalation study of XmAb819 (Clinicaltrials.gov Identifier: NCT05433142). The abstract contained a high-level safety summary across all dosing cohorts with no additional information regarding efficacy beyond what had been previously disclosed during a public webcast in September 2024. Presentation of a dataset from an updated data-cut at the conference will include a detailed safety analysis along with efficacy results from the target dose range when the embargo lifts. Management will also host a webcast and conference call to discuss the results and will provide access credentials for the event on a later date. Presentation Details Title: Preliminary Phase 1 safety and antitumor activity of XmAb819, a first-in-class ENPP3 x CD3 bispecific antibody, in patients with advanced clear cell renal cell carcinoma (ccRCC) Session: Poster Session B Date and Time: Friday, October 24, 2025 from 12:30-4:00 p.m. ET About XmAb819 XmAb819 is a first-in-class, tumor-targeted, T-cell engaging XmAb 2+1 bispecific antibody in development for patients with clear cell renal cell carcinoma (ccRCC). XmAb819 engages the immune system and activates T cells for highly potent and targeted lysis of tumor cells expressing ENPP3, an antigen highly expressed on kidney cancers. ENPP3 is a differential...

Explore Xencor's Fair Values from the Community and select yours A week ago, Xencor, Inc. (NASDAQ:XNCR) came out with a strong set of quarterly numbers that could potentially lead to a re-rate of the stock. Revenue crushed expectations at US$44m, beating expectations by 93%. Xencor reported a statutory loss of US$0.41 per share, which - although not amazing - was much smaller than the analysts predicted. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Taking into account the latest results, the current consensus, from the eleven analysts covering Xencor, is for revenues of US$138.4m in 2025. This implies a discernible 5.8% reduction in Xencor's revenue over the past 12 months. Losses are expected to increase slightly, to US$2.45 per share. Before this earnings announcement, the analysts had been modelling revenues of US$110.2m and losses of US$2.83 per share in 2025. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a sizeable increase to their revenue forecasts while also reducing the estimated loss as the business grows towards breakeven. Check out our latest analysis for Xencor Despite these upgrades,the analysts have not made any major changes to their price target of US$26.90, implying that their latest estimates don't have a long term impact on what they think the stock is worth. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. Currently, the most bullish analyst values Xencor at US$40.00 per share, while the most bearish prices it at US$6.00. As you can see the range of estimates is wide, with the lowest valuation coming in at less than half the most bullish estimate, suggesting there are some strongly diverging views on how analysts think this business will perform. As a result it might not be a great idea to make de...

PASADENA, Calif. (AP) — PASADENA, Calif. (AP) — Xencor Inc. (XNCR) on Wednesday reported a loss of $30.8 million in its second quarter. The Pasadena, California-based company said it had a loss of 41 cents per share. The results exceeded Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of 78 cents per share. The biotech developing antibodies for severe autoimmune/allergic diseases and cancer posted revenue of $43.6 million in the period, also surpassing Street forecasts. Six analysts surveyed by Zacks expected $20.1 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on XNCR at https://www.zacks.com/ap/XNCR